Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meridol Halitosis is a specialized oral hygiene product line and regimen developed by GABA International (a subsidiary of Colgate-Palmolive) specifically to address oral malodor. The system comprises a toothpaste (tooth and tongue gel), a mouthwash, a toothbrush, and a tongue cleaner. Its therapeutic efficacy is derived from a combination of active ingredients, including amine fluoride (AmF), stannous fluoride (SnF2), and zinc lactate. These components work by neutralizing volatile sulphur compounds (VSCs)—the primary chemical cause of bad breath—and by inhibiting the metabolic activity of anaerobic bacteria on the tongue and oral surfaces. Clinical evaluations, including Phase 4 studies, have confirmed its effectiveness in reducing both physiological morning breath and pathological halitosis of intra-oral origin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Meridol Halitosis.